Skin Cancer

In a recent phase 2 study, nearly half of patients who had resectable stage 3B/C BRAF V600-mutant melanoma achieved pathologic complete response (pCR) – meaning that no active cancer cells are present – with neoadjuvant combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib).

Jeffrey Weber, M.D., Ph.D., Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses how important it is that patients speak up when they experience side effects from their cancer treatments.

An injured cancer survivor reluctantly but gratefully copes with neuropathy, osteopenia and stiff-joint cancer side effects after recently breaking her foot and getting surgery.

The risk of relapse dropped 53 percent when trametinib and dabrafenib were used after therapy.

Be prepared. After cancer, other medical issues can trigger outsized emotional responses.

A new drug may be on the way to treat patients with advanced melanoma, as the FDA granted LN-144, which is produced by Iovance Biotherapeutics, a fast track designation. The drug uses tumor-infiltrating lymphocyte (TIL) technology to bolster the body’s immune system to attack cancer cells.

A cancer diagnosis robs us of many things. For an avid traveler, its like a bird being trapped in a cage.

A breast cancer and melanoma survivor who also speaks and writes about clutter clearing shares some cancer clutter clearing tips.

Melanoma survivor offers help based on her own melanoma experience and reading.

Survivor shares that there is no shame to talk to a therapist about life’s difficulties, especially when those difficulties have included coping with a cancer diagnosis and the ongoing fear of recurrence.

Cancer has a silver lining, too. Breast cancer and melanoma survivor shares hers.

Two-time cancer survivor offers help for fatigue, including fatigue that is months and years out from active treatment

Breast cancer and melanoma survivor comments on downsizing from a cancer survivor's perspective.

Breast cancer survivor approaches the phone with dread with Mom in hospice with breast cancer.

Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.

Diagnosed with desmoplastic melanoma, sportscaster Holly Rowe is working with the Melanoma Research Foundation to teach about the disease.

An immunotherapy has become the first of its kind approved to treat Merkel cell carcinoma, a rare and still mysterious skin cancer.

Creams containing the chemotherapy 5-fluorouracil can be fatal to animals, the FDA warns.

In treating rare advanced skin cancers, individualized therapy is improving outcomes.

A study pairs an IDO inhibitor with PD-1 checkpoint blockade.

Increasingly, immunotherapy drugs for advanced melanoma are being studied in combination.

During and after surgery for skin cancer, a number of strategies can help minimize scarring.

Cancer not only wages war on our bodies, but also our relationships with food. Are cancer-fighting diets really the answer?

Clinical trials are a crucial aspect in deciding therapies for patient populations with high-risk melanoma.

While the summer months are the perfect time for outdoor activities with friends and family, it is crucial to protect yourself from skin cancer.

Promising clinical activity and acceptable safety was shown when the PD-1 inhibitor Keytruda (pembrolizumab) was given with the HDAC inhibitor entinostat for patients with melanoma who were refractory to immune checkpoint inhibitors.

There is hot debate over whether full-body skin exams should be done each year to help in early detection of both non-melanoma and melanoma skin cancers.

Patients with squamous cell carcinoma of the head and neck (SCCHC) and those with melanoma saw some promising activity with the drug combination of epacadostat and Opdivo (nivolumab), according to findings from the phase 1/2 ECHO-204 study presented at the 2017 ASCO Annual Meeting.

Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a response in some patients with melanoma brain metastases, according to a recent study presented at ASCO.

A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.